NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
62
Data completeness
5/8 — Partial
Priority Review
VENCLEXTA (venetoclax) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENCLEXTA (venetoclax) is an oral BCL-2 inhibitor that works through P-glycoprotein inhibition to induce apoptosis in cancer cells. It is approved for treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in adult patients. The drug represents a targeted approach to hematologic malignancies with a well-defined mechanism of action.
$0.815BPart D
Peak7.1 years to LOEPeak lifecycle status with $815M in annual Part D spending indicates a mature, profitable product with established teams; commercial opportunities center on optimization and indication expansion rather than launch.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
BCL-2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (62)
The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
Started Nov 2026
30 enrolled
Myeloid Tumors
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
Started Nov 2026
450 enrolled
Acute Myeloid Leukaemia (AML)Acute Myeloid Leukaemia
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
Started Oct 2026
90 enrolled
AML (Acute Myeloid Leukemia)
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Started Oct 2026
155 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Worked on VENCLEXTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.